The MAX study

Interventions: The MAX study is a multi-centre, stratified, randomised, phase II/III study that aims to compare the safety and efficacy of the combination of capecitabine and bevacizumab and the combination of capecitabine, Mitomycin C (MMC) and bevacizumab, with that of capecitabine monotherapy in patients with previously untreated metastatic colorectal cancer. Treatment will continue until disease progression, unless there is unacceptable toxicity or either the patient or physician requests cessation of treatment. Primary outcome(s): Progression free survival[Measured after 450 patients have completed 1 year of follow-up] Study Design: Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Open (masking not used);Assignment: Single group;Type of endpoint: Safety/efficacy